NurExone to Showcase Its Regenerative Medicine Platform at NANO.IL.2026 and Advanced Therapies Congress in March 2026 and Provides Corporate Update
Globenewswire·2026-02-27 21:03
TORONTO and HAIFA, Israel, Feb. 27, 2026 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“NurExone” or the “Company”), a biopharmaceutical company developing exosome-based regenerative therapies, announced today its participation in two international conferences taking place in March 2026. Dr. Lior Shaltiel, PhD, Chief Executive Officer of NurExone, commented, “Engaging with scientific, industry, and investor audiences is a core part of our strategy, and March includes two ...